14-3-3η Portfolio Applications
Beyond rheumatoid arthritis, this novel portfolio of 14-3-3η-centric markers has demonstrated applications in multiple autoimmune diseases with joint involvement. The presence of one autoimmune disease carries with it a higher risk of the patient having others and rheumatic co-morbidities are particularly common in conditions such as lupus and psoriasis. The clinical utility of the 14-3-3η portfolio will transform the way patients are screened, diagnosed, risk-assessed for joint damage prognosis and monitored along their disease course. With a rapidly developing data set, the 14-3-3η portfolio is expected to transform the management of multiple autoimmune diseases in the years to come, along multiple testing formats for ease of patient access.
Comments are closed.